ReviewInternational journal of molecular sciences2018
Harmful Effects and Potential Benefits of Anti-Tumor Necrosis Factor (TNF)-α on the Liver.
Review in International journal of molecular sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 3 syntheses or guidelines pooled it, 87 citations in OpenAlex.
- Prevalence of non-alcoholic fatty liver disease among inflammatory bowel disease patients: a systematic review and meta-analysis.Frontiers in medicine · 2025Pooled it
- Efficacy and safety of Iguratimod in the treatment of Ankylosing Spondylitis: A systematic review and meta-analysis of randomized controlled trials.Frontiers in immunology · 2023Pooled it
- Meta-analysis: prevalence of, and risk factors for, non-alcoholic fatty liver disease in patients with inflammatory bowel disease.Alimentary pharmacology & therapeutics · 2022Pooled it
- Iguratimod in Autoimmune Diseases: Emerging Evidence for its Immunomodulatory and Therapeutic Role.Mediterranean journal of rheumatology · 2026Review
- Adalimumab Safety in Inflammatory Bowel Disease: A Clinical Cohort Study with Time-to-Event Analysis and FAERS Signal Assessment.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Exploring Toxicological Mechanisms of Typical PFAS-Induced NAFLD through Integrated Computational Toxicology and AOP Frameworks.Environment & health (Washington, D.C.) · 2026Article
- Time-dependent modulation of FXR and Nrf2 signaling in rat models of BDL-induced cholestasis.Iranian journal of basic medical sciences · 2026Article
- Three-year outcomes of tumor necrosis factor alpha inhibitor therapy in rheumatoid arthritis patients with elevated liver enzymes.World journal of hepatology · 2025Article
- Baseline Pathological Liver Function Tests in Patients With Psoriasis Support the Indication for Systemic Therapy Rather Than Being a Reason Against It: A Real-World Analysis.Psoriasis (Auckland, N.Z.) · 2025Article
- Focus on Anti-Tumour Necrosis Factor (TNF)-α-Related Autoimmune Diseases.International journal of molecular sciences · 2023Review
- Psoriatic disease and non-alcoholic fatty liver disease shared pathogenesis review.Seminars in arthritis and rheumatism · 2023Review
- Hepatoprotective Effects of Rosmarinic Acid on Ovalbumin-Induced Intestinal Food Allergy Mouse Model.Molecules (Basel, Switzerland) · 2023Article
- Current knowledge of TNF-α monoclonal antibody infliximab in treating Kawasaki disease: a comprehensive review.Frontiers in immunology · 2023Review
- Research on Liver Damage Caused by the Treatment of Rheumatoid Arthritis with Novel Biological Agents or Targeted Agents.Journal of inflammation research · 2023Review
- Integrated strategy of RNA-sequencing and network pharmacology for exploring the protective mechanism of Shen-Shi-Jiang-Zhuo formula in rat with non-alcoholic fatty liver disease.Pharmaceutical biology · 2022Article
- Liver-specific drug delivery platforms: Applications for the treatment of alcohol-associated liver disease.World journal of gastroenterology · 2022Review
- Label-free metabolic imaging of non-alcoholic-fatty-liver-disease (NAFLD) liver by volumetric dynamic optical coherence tomography.Biomedical optics express · 2022Article
- Hepatotoxicity Induced by Biological Agents: Clinical Features and Current Controversies.Journal of clinical and translational hepatology · 2022Review
- Paradoxical Reactions to Biologicals in Chronic Inflammatory Systemic Diseases.Deutsches Arzteblatt international · 2022Article
- Antifibrotic preventive effect of polyethylene glycol (PEG) 3350 in methotrexateinduced hepatoxicity model.Acta cirurgica brasileira · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anti-tumor necrosis factor (TNF)-α agents represent an effective treatment for chronic inflammatory diseases. However, some concerns about their potentially undesirable effects on liver function have been reported. On the other hand, evidence of their therapeutic effects on certain liver diseases is accumulating. Many data showed the safety of anti-TNF-α in patients with chronic hepatitis B and C and in liver transplanted patients even if a strict follow-up and prophylaxis are recommended in well-defined subgroups. On the other side, anti-TNF-α-induced liver injury is not a rare event. However, it is often reversible after anti-TNF-α withdrawal. Anti-TNF-α agents have been tested in advanced stages of severe alcoholic hepatitis and non-alcoholic fatty liver disease. Limited data on the efficacy of anti-TNF-α in patients with autoimmune hepatitis and primary biliary cholangitis are also available. In this review, we explored the hepatic safety concerns in patients receiving anti-TNF-α agents with and without pre-existent hepatic diseases. In addition, the available evidence on their potential benefits in the treatment of specific hepatic diseases is discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.